Form 8-K · Current Report · Filed 2026-08-17
Illumina, Inc. Completes Issuance of $300 Million in New Notes
On August 17, 2026, Illumina, Inc. completed the issuance of $300,000,000 aggregate principal amount of its 4.950% notes due 2029. The company intends to use the net proceeds, along with cash on hand, to repay its 4.650% notes due September 9, 2026. The new notes will accrue interest at a rate of 4.950% per annum, payable semi-annually, and will mature on September 19, 2029. The issuance was made pursuant to an Indenture dated March 12, 2021, between the company and U.S. Bank Trust Company, National Association, as trustee.
- Filer
- Illumina, Inc. ILMN · NASDAQ
- Filed
- Accession
- 0001193125-26-354010
- CIK
- 0001110803
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$190.89
Since filing
+0.0%
Latest close
$190.89
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ILMN reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ILMN insiders reported 18 Form 4 transactions — net selling of $147.4M.
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Never miss another ILMN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.